Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 7 W ELECTROLYTES versus TRAVASOL 10 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN II 7 W ELECTROLYTES versus TRAVASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 7% W/ ELECTROLYTES vs TRAVASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Travasol 10% (amino acids injection) provides essential and non-essential amino acids for protein synthesis and nitrogen equilibrium in patients unable to obtain adequate nutrition orally or enterally. Amino acids are building blocks for proteins; they also serve as substrates for gluconeogenesis and other metabolic pathways.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
Intravenous infusion: 500 mL to 2 L per day, administered at a rate not exceeding 4 mL/kg/h. Typical adult dose is 1-2 g protein/kg/day (equivalent to 10-20 mL/kg/day of 10% solution). Rate and volume are adjusted based on patient's metabolic needs and clinical status.
None Documented
None Documented
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Not applicable as a single entity; constituent amino acids have half-lives varying from minutes to hours (e.g., 10-30 min for most). Clinical context: continuous infusion maintains steady state.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Renal excretion of infused amino acids and their metabolites; excess nitrogen excreted as urea in urine. ~90-95% of infused amino acids are utilized or excreted renally. Fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution